Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268500 · ClinicalTrials.gov registry record · Phase 4
VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
NCT02268500 is a Phase 4 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 48 participants.
The verdict
NCT02268500, a Phase 4 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
Study Summary
A multi-center, prospective, randomized, open-label blinded-endpoint trial in patients with heart failure will be conducted; 20 will be assigned to the standard dose vaccine dose and 20 patients to high dose influenza vaccine. Post-vaccine antibody measurements will be assessed, as well as tolerability differences between groups.
Interventions
- BIOLOGICAL Influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02268500
The ClinicalTrials.gov registry entry for NCT02268500 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza vaccine is the first listed.
NCT02268500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02268500 about?
NCT02268500 is a clinical study titled "VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)". A multi-center, prospective, randomized, open-label blinded-endpoint trial in patients with heart failure will be conducted; 20 will be assigned to the standard dose vaccine dose and 20 patients to high dose influenza vaccine. Post-vaccine antibody measurements will be assessed, as well as tolerabil...
What is the current status of trial NCT02268500?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2014-09. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02268500?
The interventions under investigation include: Influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02268500?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.